Saturday, July 30, 2011
Novel gene therapy for HIV(Bone marrow transplant 'cures HIV patient' )
Novel gene therapy for HIV(Bone marrow transplant 'cures HIV patient' )
Muhammed Ishad*,Megha.M, Nayanathara P.S, Dilip.C, P.N. Krishnan, Junise.V
Al shifa college of pharmacy, poonthavanam, perinthalmanna,kerala.
Abstract
The "Berlin Patient" -- now known to be Timothy Ray Brown -- remains free of any detectable HIV in his blood, gut tissue, and other reservoir sites 4 years after receiving a bone marrow transplant containing stem cells from a donor with the CCR5-delta32 mutation, according to a report in the December 8, 2010 advance online edition of Blood. These findings, his doctors say, "strongly suggest that cure of HIV has been achieved in this patient."
INTRODUCTION
Two million people die of Aids every year and HIV is estimated to have infected 33 million people worldwide. [1] Doctors in Germany say a patient (42-year-old patient was an American living in Berlin) appears to have been cured of HIV by a bone marrow transplant from a donor who had a genetic resistance to the virus [2]. The researchers in Berlin said the man, who suffered from leukaemia and HIV, had shown no sign of either disease since the transplant two years ago.HIV requires one of 2 co-receptors, CCR5 or CXCR4, to enter human cells. Individuals with a natural genetic mutation known as CCR5-delta32, who do not express CCR5 on their CD4 T-cells, are resistant to HIV infection.[3] Those who do become infected may be "elite controllers" who maintain very low viral load without antiretroviral therapy (ART).
CASE STUDY
A berlin HIV +ve Patient underwent leukemia treatment that involves using potent chemotherapy to kill off immune cells -- which eliminates the cancer -- and reconstituting the immune system with donated hematopoietic stem cells, which differentiate into all the different types of blood cells, including T-cells.After the first transplant, researchers were unable to find any evidence of HIV, even though the patient stopped taking ART. He then received a second transplant from the same donor due to a relapse of leukemia. He had been infected with the human immunodeficiency virus, that causes Aids, for more than a decade and also had leukaemia. The clinic said since the transplant was carried out 20 months ago, tests on the patient's bone marrow, blood and other organ tissues have all been clear.
RESULT
"Results demonstrate successful CD4+ T-cell reconstitution at the systemic level as well as in the largest immunologic organ [the gut] following CCR5-delta32/delta32 stem cell transplant, and additionally provide evidence for the reduction in the size of the potential HIV reservoir over time," they elaborated in their discussion.
The Berlin Patient, however, shows no evidence of residual HIV and has not experienced disease progression.
His immune system was successfully reconstituted, and now contains HIV-resistant CCR5-delta32 cells, like those of the donor.
Furthermore, the researchers noted, "We found evidence for the replacement of long-lived host tissue cells with donor-derived cells indicating that the size of the viral reservoir has been reduced over time."
CONCLUSION
Although the recovered CD4+ T-cells are susceptible to infection with [CXCR4] HIV infection, the patient remains without any evidence for HIV infection since more than 3.5 years after discontinuation of ART," the researchers concluded. "From these results, it is reasonable to conclude that cure of HIV infection has been achieved in this patient."
References.
1) Fauci AS,Lane HC.Human immune deficiency virus disease: AIDS and related disorders.In: Kasper,Braunwald,Fauci,Hauser,Longo,Jameson,Harrisons principle of internal medicine 17th ed. Newyork Mc Graw-Hill; 2005.p.1137-1148
2) Shelburne SA,Visnegarwala F,Darcourt J,Graviss EA,Giordano TP,White AC Jr,
et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.AIDS 2005,19:399-406
Muhammed Ishad,
M Pharm 1st year
Alshifa college of pharmacy,
Dilip.c
Associate prof
Alshifa college of pharmacy
Monday, June 27, 2011
Department of pharmacy practice,Al shifa college of pharmacy
DEPARTMENT OF PHARMACY PRACTICE
The mission of the Department of Pharmacy Practice in Al Shifa hospital is to
1) Prepare students for entry into the pharmacy profession in an environment that supports and inspires critical thinking, life-long learning, leadership and professionalism
2) Create and disseminate knowledge related to the rational use, delivery and access to drugs and other therapeutic modalities and 3)Provide service and leadership to the university community, the profession of pharmacy and the public related to education and the optimal use of medications
About the Department
The Department of Pharmacy Practice is an academic department in the Al Shifa College of Pharmacy located in kizhatoor campus under Calicut University and also has facilities in Al Shifa Hospital in Perinthalmanna. The mission of the Department of Pharmacy Practice is to demonstrate excellence through performance in the areas of discovery, learning, and engagement.
The Department of Pharmacy Practice supports the College of Pharmacy's vision by:
* Providing education to students that enable them to acquire in-depth expertise in the pharmaceutical, social/economic management, and related sciences in order to function as educators and scientists in higher education, government service, and the pharmaceutical and healthcare industries
* Serving the community by engaging in scholarly activities that lead to improvements in healthcare delivery and enhance health outcomes
* Fostering innovation in research through interdisciplinary collaboration with other schools/colleges within other national/international universities, and pharmacy practitioners to enhance to profession body of knowledge resulting in practice advancement
* Contributing to the profession of pharmacy by participation in leadership roles in pharmaceutical organizations and community programs
DILIP.C
ASST PROFESSOR
ALSHIFA COLLEGE OF PHARMACY
PERINTHALMANNA, KERALA
pharm D in India.,Al shifa college of pharmacy
Pharm.D
As a part of our expansion programme and with a mission to serve the community as a whole, We have introduced Pharm D in Alshifa College of pharmacy, which to our expectation will produce more number of trained quality pharma professionals in coming years. We have ample infrastructure focusing mainly on clinical aspects. The introduction of the Pharm D. course is set to change the country’s pharmacy education landscape. The introduction of Pharm.D, a six year integrated postgraduate programme, is expected to take the country’s pharmacy education to international levels. Pharm D. is a six year course providing intensive training in pharmacy practice and clinical pharmacy services. The course will include five years of clinical and community-based theory with ward rounds and one year internship in hospitals. Pharm D. students will work in coordination with doctors to treat patients. In the final year, the student will come out as a clinical pharmacist who will be an essential component of healthcare equal to doctors. Pharm D. graduates will study in detail about drugs for different diseases, will advise patients about dose, action, and side effects and has knowledge and skills of current diagnostic methods, treatment modalities, drug delivery system, therapeutics outcome, pharmaco economics and pharmaco therapy to meet the rapid changes in the healthcare system.
A pharmacist is a vital link in the physician-patient chain and he is expected to play a key role in the dissemination of pharmaceutical knowledge. The practice of pharmacy includes the custody, preparation and distribution of pharmaceutical products besides providing advice on health and nutrition related issues. Al Shifa College of Pharmacy at Perinthalmanna in Malappuram district is the only college in the State to get the PCI approval this year. We are the only college in kerala giving 50% Govt merit seat for poor and meritorious students for improving the health care status of the state .Alshifa college is attached to a 450-beded tertiary care referral hospital.
The final outcome of the Pharm.D course
1. Pharmaceutical care to patient by integrating pharmacy into every day functioning of hospital and patient care, to be an essential part of heath care team.
2. Developing and managing medication, distribution and control systems. Further ensure correct storage, expiry dates and maintenance of documentation.
3. Maintaining of patient after medication, analyzing, reporting medication errors. Preparing policies, procedures for safe use of high risk medication, blood products, chemotherapeutic agents, radioactive isotopes, investigational new drug and medicinal gases.
4. Promoting public health, patient counseling, and food drug interaction drug drug interaction.
providing drug information, poison information, education to health care team and stake holder (patients)
5. Managing the pharmacy.
Dilip.c
Asst professor
Al-shifa college of pharmacy
perinthalmanna, kerala.
Wednesday, April 13, 2011
Banned Drugs (10th February 2011)
NOTIFICATION
Banned Drugs (10th February 2011)
In exercise of the powers conferred by section 26a of the drugs and cosmetics act, 1940(23 0f 1940), the central Govt hereby prohibits the manufacture, sale and distribution of the following drugs with immediate effect, namely
1. Nimesulide formulations for human use in children below 12 years of age.
2. Cisapride and its formulations for human use
3. Phenylpropanolamine and its formulations for human use.
4. Human placental extract and its formulations for human use
5. Sibutramine and its formulations for human use
6. R-sibutramine and its formulations for human use.
DILIP.C
ASST PROF
ALSHIFA COLLEGE OF PHARMACY
DILIP.C
ASST PROF
ALSHIFA COLLEGE OF PHARMACY
Subscribe to:
Posts (Atom)